@article{oai:niigata-u.repo.nii.ac.jp:00010516,
 author = {下条, 文武},
 issue = {12},
 journal = {新潟医学会雑誌, 新潟医学会雑誌},
 month = {Dec},
 note = {My academic and research career on dialysis-related amyloidosis was described in the final lecture as my professor retirement from the Department of Internal Medicine II. Dialysis-related amyloidosis has been becoming a frequent and serious complication in patients on long-term hemodialysis around 1980～1985. We have identified β_2-microglobulin (β_2-m) biochemically as the major protein constituent of the amyloid fibrils in 1985. Since β_2-m is a major structural component of this type of amyloidosis, serum β_2-m is thought to be a precursor protein. A negative correlation has been demonstrated between serum β_2-m concentration and glomerular filtration rate in chronic renal failure peatients. After the start of hemodialysis, serum β_2-m concentrations show a rapid increase and become markedly elevated, exceeding the upper limit of normal by 40 times or more. This indicates that removal of β_2-m from the blood is an important therapeutic approach to this form of amyloidosis. Clinical therapeutic strategies for dialysis-related amyloidosis have attempted to remove β_2-m from the serum by using high-flux membrane dialyzers. We have investigated the clinical efficacy of direct hemoperfusion with a β_2-m adsorption column in the patients with dialysis-related amyloidosis. Finally, we have demonstrated the column is useful for preventing progression of dialysis-related amyloidosis and in ameliorating or arresting symptoms of this disorder. It will be helpful to establish more effective prevention and therapy in the future.},
 pages = {599--604},
 title = {最終講義 : 我が学問 : 透析アミロイドーシスの研究と共に},
 volume = {123},
 year = {2009}
}